Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) — Working Capital to Net Assets Ratio
Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) has a Working Capital to Net Assets ratio of 13.6% as of March 2026. Working capital of CN¥198.18 Million (current assets of CN¥464.31 Million minus current liabilities of CN¥266.14 Million) is measured against net assets of CN¥1.46 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Zhejiang Cheng Yi Pharmaceutical Co Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Cheng Yi Pharmaceutical Co Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Zhejiang Cheng Yi Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 13.6%, reflecting working capital of CN¥198.18 Million against net assets of CN¥1.46 Billion CNY. See Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Zhejiang Cheng Yi Pharmaceutical Co Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Cheng Yi Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Zhejiang Cheng Yi Pharmaceutical Co Ltd market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 9.2% | CN¥129.16 Million | CN¥1.40 Billion | CN¥395.49 Million | CN¥266.33 Million | ▲ +1.2 pp |
| 2024 | 8.1% | CN¥102.12 Million | CN¥1.27 Billion | CN¥393.62 Million | CN¥291.50 Million | ▼ -6.5 pp |
| 2023 | 14.6% | CN¥174.78 Million | CN¥1.20 Billion | CN¥517.42 Million | CN¥342.65 Million | ▼ -1.8 pp |
| 2022 | 16.4% | CN¥178.85 Million | CN¥1.09 Billion | CN¥436.84 Million | CN¥257.99 Million | ▲ +12.3 pp |
| 2021 | 4.1% | CN¥40.93 Million | CN¥998.88 Million | CN¥287.80 Million | CN¥246.87 Million | ▼ -2.1 pp |
| 2020 | 6.2% | CN¥54.93 Million | CN¥886.09 Million | CN¥282.31 Million | CN¥227.38 Million | ▼ -8.8 pp |
| 2019 | 15.0% | CN¥114.98 Million | CN¥768.96 Million | CN¥317.18 Million | CN¥202.20 Million | ▼ -15.7 pp |
| 2018 | 30.6% | CN¥206.25 Million | CN¥673.54 Million | CN¥343.82 Million | CN¥137.57 Million | ▼ -35.5 pp |
| 2017 | 66.1% | CN¥396.34 Million | CN¥599.57 Million | CN¥467.23 Million | CN¥70.88 Million | ▲ +30.7 pp |
| 2016 | 35.4% | CN¥99.25 Million | CN¥280.17 Million | CN¥181.00 Million | CN¥81.75 Million | ▲ +3.4 pp |
| 2015 | 32.0% | CN¥83.26 Million | CN¥259.92 Million | CN¥167.71 Million | CN¥84.45 Million | ▲ +5.0 pp |
| 2014 | 27.1% | CN¥66.85 Million | CN¥246.95 Million | CN¥147.96 Million | CN¥81.11 Million | ▲ +10.4 pp |
| 2013 | 16.6% | CN¥33.49 Million | CN¥201.40 Million | CN¥165.32 Million | CN¥131.83 Million | ▲ +0.8 pp |
| 2012 | 15.8% | CN¥28.19 Million | CN¥178.13 Million | CN¥207.54 Million | CN¥179.35 Million | ▲ +56.1 pp |
| 2011 | -40.3% | CN¥-41.34 Million | CN¥102.60 Million | CN¥151.22 Million | CN¥192.56 Million | — |